Meeting
2024 ASCO Annual Meeting
Development of a novel risk stratification model for immune-related adverse events for patients with advanced melanoma and non-small cell lung cancer treated with immune checkpoint inhibitors.
Authors
Yizhuo Kelly Gao
University of Calgary, Cumming School of Medicine, Calgary, AB, Canada
Yizhuo Kelly Gao , Andrew Tran , Mehul Gupta , Daniel Yick Chin Heng , Tina Cheng , Igor Stukalin , Daniel E. Meyers , Winson Y. Cheung , Jose Gerard Monzon , Vishal Navani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2649)
DOI
10.1200/JCO.2024.42.16_suppl.2649
Abstract #
2649
Poster Bd #
128
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC.
First Author: Sally CM Lau
Poster
2019 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
First Author: Andreas Nicholas Saltos
Poster
2024 ASCO Breakthrough
Dietary pattern and the corresponding gut microbiome in response to immunotherapy in Thai patients with advanced non-small cell lung cancer (NSCLC).
First Author: Piyada Sitthideatphaiboon
Poster
2024 ASCO Genitourinary Cancers Symposium
AIM high: Epigenetic modulation and immune stimulation in bladder cancer.
First Author: Elizabeth Leone Koehne